Sunrise Global Exim

Wegovy 2.4 mg FlexTouch (Semaglutide 2.4 mg) is a prescription, once-weekly injectable medication approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) who have at least one weight-related condition such as type 2 diabetes, high blood pressure, or abnormal cholesterol levels. It contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that helps regulate appetite and calorie intake.

The 2.4 mg dose is the recommended maintenance dose of Wegovy therapy. Patients typically begin treatment at a lower dose of 0.25 mg once weekly and gradually increase every four weeks (0.5 mg, 1 mg, 1.7 mg) before reaching 2.4 mg. This stepwise dose escalation helps minimize gastrointestinal side effects and allows the body to adapt to the medication.

Semaglutide works by mimicking the natural GLP-1 hormone released after meals. It acts on appetite-regulating centers in the brain to reduce hunger, control cravings, and increase feelings of fullness. In addition, it slows gastric emptying, meaning food stays in the stomach longer, which prolongs satiety after eating. These combined effects lead to reduced calorie intake and support sustained weight loss when used alongside a reduced-calorie diet and increased physical activity.

Clinical studies have shown that patients taking Wegovy 2.4 mg can achieve significant and sustained weight reduction compared to lifestyle changes alone. Many individuals experience meaningful improvements not only in body weight but also in blood pressure, blood sugar levels, and cholesterol values. However, results vary from person to person and depend on adherence to medication and lifestyle modifications.

The FlexTouch pen is a prefilled, easy-to-use device designed for convenient self-administration. Wegovy 2.4 mg is injected subcutaneously (under the skin) once weekly in the abdomen, thigh, or upper arm. It may be administered at any time of day, with or without food, but should be given on the same day each week. Rotating injection sites is recommended to reduce irritation.

Common side effects include nausea, vomiting, diarrhea, constipation, abdominal discomfort, and decreased appetite. These gastrointestinal symptoms are generally mild to moderate and often improve over time. Eating smaller meals and avoiding high-fat foods may help reduce side effects.

Serious but less common risks include pancreatitis, gallbladder disease, kidney problems related to dehydration, and a potential increased risk of thyroid tumors. Wegovy is not recommended for individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. It should not be used during pregnancy, and women of childbearing age should discuss contraception with their healthcare provider.

In summary, Wegovy 2.4 mg FlexTouch (Semaglutide 2.4 mg) is the full maintenance dose for chronic weight management, offering substantial appetite control and clinically significant weight loss when used under medical supervision as part of a comprehensive lifestyle program.